Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.34 |
| ▸ | FAAH | O00519 | 8/20 | 0.33 |
| ▸ | CES1 | P23141 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6256090 | 0.86 | CES2 (0.41) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL6256085 | 0.86 | CES2 (0.41) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL9508964 | 0.86 | CES2 (0.41) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL9512023 | 0.84 | CES2 (0.48) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL6250222 | 0.82 | CES2 (0.52) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL9508334 | 0.82 | CES2 (0.52) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL9508938 | 0.82 | CES2 (0.52) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL6251804 | 0.82 | CES2 (0.52) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL9511027 | 0.82 | CES2 (0.52) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL6250219 | 0.82 | CES2 (0.52) | CES2FAAHCES1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643289-B1 | PROCESS FOR PRODUCING PERFLUORINATED ORGANIC COMPOUNDS | SOLVAY SPECIALTY POLYMERS IT (IT) | 2018-01-24 | — | — | EP | disclosed |
| US-9051259-B2 | Process for producing perfluorinated organic compounds | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2015-06-09 | — | — | US | disclosed |
| EP-2643289-A1 | PROCESS FOR PRODUCING PERFLUORINATED ORGANIC COMPOUNDS | Solvay Specialty Polymers Italy S.p.A. (IT) | 2013-10-02 | — | — | EP | disclosed |
| US-20130245289-A1 | Process for producing perfluorinated organic compounds | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2013-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245289-A1 | Process for producing perfluorinated organic compounds | PFAS, ADH1A, CYP2F1 | CES2 31/4885FAAH 230/4885CES1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.